Actively Recruiting
Phase 1 Study of LY3439539 IV Treatment in People Aged 50 to 85 With Alzheimers Disease Monitoring Changes in Spinal Fluid Proteins Over 9 Months
Led by Eli Lilly and Company · Updated on 2026-08-07
30
Participants Needed
8
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the effects of LY3439539 on specific proteins found in the spinal fluid of people with Alzheimers disease. This phase 1, open-label study focuses on understanding how this investigational drug changes cerebrospinal fluid biomarkers related to Alzheimers. Participants will have symptomatic Alzheimers and meet specific memory and biomarker criteria to join the study. Participants will receive LY3439539 through intravenous IV administration. The treatment involves multiple doses, and the study is designed as a single group where all participants receive the same drug. The study lasts about 9 months, with visits approximately once a month to monitor treatment and collect necessary data. During the study, participants will undergo assessments including cerebrospinal fluid and blood tests to measure changes in biomarkers like neurofilament light chain and phospho-Tau. Researchers will also monitor the drugs concentration in the blood. Participants will have support from study partners and will be evaluated regularly for safety and treatment effects throughout the study period and follow-up.
CONDITIONS
Brief Title
A Study of LY3439539 in Participants With Alzheimer's Disease
Research Team
T
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
P
Physicians interested in becoming principal investigators please contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
